
Joaquim Bellmunt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8295683/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	13.7	3,077
2	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	27.0	2,677
3	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2017, 71, 618-629.	1.9	2,497
4	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515, 558-562.	27.8	2,109
5	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	28.9	1,742
6	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	13.7	1,728
7	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013. European Urology, 2014, 65, 124-137.	1.9	1,613
8	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European Urology, 2014, 65, 467-479.	1.9	1,304
9	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. European Urology, 2011, 59, 61-71.	1.9	1,299
10	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. European Urology, 2017, 71, 630-642.	1.9	1,215
11	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 1483-1492.	10.7	1,034
12	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2020, 383, 1218-1230.	27.0	802
13	Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. Journal of Clinical Oncology, 2010, 28, 2144-2150.	1.6	767
14	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	1.9	741
15	Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract. Journal of Clinical Oncology, 2009, 27, 4454-4461.	1.6	687
16	Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology, 2012, 30, 191-199.	1.6	613
17	Treatment of Patients With Metastatic Urothelial Cancer "Unfit―for Cisplatin-Based Chemotherapy. Journal of Clinical Oncology, 2011, 29, 2432-2438.	1.6	514
18	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European Urology, 2011, 59, 572-583.	1.9	459

#	Article	IF	CITATIONS
19	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	21.4	438
20	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine, 2012, 18, 221-223.	30.7	434
21	Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology, 2012, 30, 1107-1113.	1.6	428
22	Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. Journal of Clinical Oncology, 2010, 28, 2280-2285.	1.6	400
23	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	3.4	354
24	Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. European Urology, 2014, 66, 42-54.	1.9	349
25	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 84-109.	1.9	348
26	Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. Journal of Clinical Oncology, 2010, 28, 1850-1855.	1.6	340
27	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1574-1588.	10.7	324
28	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2017, 18, 212-220.	10.7	307
29	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. European Urology, 2017, 72, 250-266.	1.9	305
30	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature, 2021, 595, 432-437.	27.8	293
31	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncology, The, 2011, 12, 211-214.	10.7	261
32	Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2011, 29, 632-638.	1.6	259
33	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	1.6	229
34	Emergence of Multiple <i>EGFR</i> Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 2157-2166.	7.0	227
35	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	7.0	225
36	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	10.7	225

#	Article	IF	CITATIONS
37	Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. , 1997, 80, 1966-1972.		221
38	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncology, The, 2011, 12, 1143-1150.	10.7	217
39	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2012, 62, 523-533.	1.9	214
40	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncology, The, 2013, 14, 1307-1316.	10.7	205
41	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. European Urology, 2014, 66, 569-576.	1.9	205
42	A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 529-541.	1.9	205
43	Clinical Validation of Chemotherapy Response Biomarker <i>ERCC2</i> in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncology, 2016, 2, 1094.	7.1	205
44	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
45	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	7.0	193
46	Management of metastatic bladder cancer. Cancer Treatment Reviews, 2019, 76, 10-21.	7.7	190
47	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2020, 38, 2658-2666.	1.6	186
48	Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer. Urology, 2007, 69, 62-79.	1.0	183
49	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 869-885.	1.9	182
50	Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial. Journal of Clinical Oncology, 2014, 32, 752-759.	1.6	179
51	Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. Journal of Clinical Oncology, 2015, 33, 643-650.	1.6	165
52	Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer "Unfit―for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986. Journal of Clinical Oncology, 2009, 27, 5634-5639.	1.6	161
53	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscleâ€nvasive bladder cancer. Cancer, 2015, 121, 2586-2593.	4.1	155
54	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings. European Urology, 2013, 63, 58-66.	1.9	151

#	Article	IF	CITATIONS
55	The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. European Urology, 2019, 75, 961-964.	1.9	141
56	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	4.1	138
57	Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162.	1.2	137
58	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 417-425.	10.7	137
59	Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer, 2002, 95, 751-757.	4.1	133
60	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 2014, 50, 1617-1627.	2.8	133
61	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
62	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 257-262.	1.6	127
63	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. Journal of Clinical Oncology, 2015, 33, 723-731.	1.6	127
64	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. European Urology, 2011, 60, 684-690.	1.9	125
65	Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature. European Urology, 2012, 62, 290-302.	1.9	121
66	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. European Urology, 2011, 59, 526-540.	1.9	119
67	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	1.9	110
68	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. European Urology, 2018, 73, 40-50.	1.9	107
69	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. European Urology, 2013, 63, 717-723.	1.9	104
70	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	1.6	104
71	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer. JAMA Oncology, 2018, 4, 537.	7.1	104
72	<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 977-988.	7.0	104

#	Article	IF	CITATIONS
73	Endobronchial metastatic disease: Analysis of 32 cases. , 1996, 62, 249-252.		103
74	EORTC-GU group expert opinion on metastatic renal cell cancer. European Journal of Cancer, 2009, 45, 765-773.	2.8	103
75	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clinical Cancer Research, 2019, 25, 2458-2470.	7.0	102
76	Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. European Urology, 2021, 79, 635-654.	1.9	102
77	New Therapeutic Challenges in Advanced Bladder Cancer. Seminars in Oncology, 2012, 39, 598-607.	2.2	100
78	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications, 2017, 8, 2193.	12.8	99
79	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	1.6	97
80	The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce. Critical Reviews in Oncology/Hematology, 2009, 69, 64-72.	4.4	93
81	Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews, 2010, 36, 416-424.	7.7	89
82	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
83	Impact of surgeon volume on the morbidity and costs of radical cystectomy in the <scp>USA</scp> : a contemporary populationâ€based analysis. BJU International, 2015, 115, 713-721.	2.5	79
84	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 2020, 38, 4064-4075.	1.6	78
85	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	2.5	76
86	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine, 2014, 3, 835-844.	2.8	76
87	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
88	Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. European Urology, 2016, 69, 802-820.	1.9	75
89	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews, 2020, 82, 101925.	7.7	73
90	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	1.6	70

#	Article	IF	CITATIONS
91	Diagnostic Value of Bronchoalveolar Lavage in Peripheral Lung Cancer. The American Review of Respiratory Disease, 1993, 147, 649-652.	2.9	69
92	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.		68
93	Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs, 2017, 77, 1077-1089.	10.9	67
94	Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 84572-84578.	1.8	66
95	The evolving understanding of microRNA in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 41.e31-41.e40.	1.6	65
96	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nature Medicine, 2021, 27, 2200-2211.	30.7	65
97	Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic) Tj ETQq1 1 0.78431 2010, 11, 350-357.	.4 rgBT /O 10.7	verlock 10 Tf 64
98	Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nature Medicine, 2016, 22, 685-691.	30.7	64
99	Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012 Journal of Clinical Oncology, 2015, 33, 4502-4502.	1.6	64
100	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis Journal of Clinical Oncology, 2020, 38, LBA1-LBA1.	1.6	64
101	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2013, 87, 80-89.	4.4	63
102	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	7.0	63
103	Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology, 2020, 13, 1-6.	3.1	63
104	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma Journal of Clinical Oncology, 2017, 35, 305-305.	1.6	63
105	Experience with sorafenib and adverse event management. Critical Reviews in Oncology/Hematology, 2011, 78, 24-32.	4.4	62
106	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	1.9	62
107	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	1.9	61
108	New treatment options for metastatic renal cell carcinoma. ESMO Open, 2017, 2, e000185.	4.5	60

#	Article	IF	CITATIONS
109	Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open, 2016, 1, e000126.	4.5	59
110	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	5.4	59
111	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. British Journal of Cancer, 2020, 122, 555-563.	6.4	59
112	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 5775.	12.8	59
113	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	7.1	58
114	Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU International, 2007, 99, 274-280.	2.5	56
115	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology, 2017, 71, 281-289.	1.9	56
116	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. Journal of Urology, 2016, 195, 277-282.	0.4	54
117	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist, 2017, 22, 286-292.	3.7	54
118	The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2011, 60, 270-278.	1.9	53
119	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with firstâ€line sunitinib: a medical chart review across ten centers in five European countries. Cancer Medicine, 2014, 3, 1517-1526.	2.8	53
120	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. European Urology, 2016, 69, 634-641.	1.9	53
121	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	1.6	52
122	New agents for prostate cancer. Annals of Oncology, 2014, 25, 1700-1709.	1.2	51
123	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2017, 15, 23-30.e2.	1.9	50
124	Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. European Urology, 2015, 67, 866-873.	1.9	49
125	Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 12-17.	3.4	49
126	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA;) Tj ETQq0 0	0 rgBT /Ove 10 . 7	rlocန 10 Tf 5C

2017, 18, 672-681a.

#	Article	IF	CITATIONS
127	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 4476-4486.	0.9	49
128	Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) Journal of Clinical Oncology, 2014, 32, 5011-5011.	1.6	49
129	Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) Journal of Clinical Oncology, 2017, 35, 4502-4502.	1.6	49
130	Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches. Current Oncology Reports, 2011, 13, 216-221.	4.0	48
131	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. European Urology, 2017, 71, 168-171.	1.9	48
132	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 368-380.	1.9	48
133	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treatment Reviews, 2010, 36, 16-23.	7.7	46
134	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports, 2016, 6, 27702.	3.3	46
135	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncology, The, 2018, 19, e317-e326.	10.7	46
136	Urothelial carcinoma management in elderly or unfit patients. European Journal of Cancer, Supplement, 2016, 14, 1-20.	2.2	45
137	IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2016, 34, 355-355.	1.6	45
138	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferonâ€i±2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU International, 2011, 107, 214-219.	2.5	43
139	Adrenocortical carcinoma: The management of metastatic disease. Critical Reviews in Oncology/Hematology, 2014, 92, 123-132.	4.4	43
140	A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC) Journal of Clinical Oncology, 2015, 33, 4501-4501.	1.6	43
141	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) Journal of Clinical Oncology, 2020, 38, 5000-5000.	1.6	43
142	Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population Journal of Clinical Oncology, 2017, 35, 284-284.	1.6	42
143	<scp>HER2</scp> as a target in invasive urothelial carcinoma. Cancer Medicine, 2015, 4, 844-852.	2.8	41
144	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. European Urology Oncology, 2020, 3, 94-101.	5.4	41

#	Article	IF	CITATIONS
145	A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 310-319.	7.7	40
146	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	1.9	40
147	SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 61-83.	2.2	40
148	The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU International, 2009, 103, 572-577.	2.5	39
149	Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB). Oncology, 2013, 85, 208-215.	1.9	39
150	The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients. Current Oncology Reports, 2012, 14, 295-306.	4.0	38
151	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 2019, 125, 533-540.	4.1	38
152	Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opinion on Drug Safety, 2011, 10, 645-653.	2.4	37
153	Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. European Journal of Cancer, 2012, 48, 1816-1821.	2.8	37
154	Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 469.e1-469.e11.	1.6	37
155	The medical management of prostate cancer: a multidisciplinary team approach. BJU International, 2007, 99, 22-27.	2.5	36
156	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational New Drugs, 2012, 30, 729-740.	2.6	36
157	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 820-824.	4.9	36
158	Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer Journal of Clinical Oncology, 2017, 35, TPS4590-TPS4590.	1.6	36
159	Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) Journal of Clinical Oncology, 2018, 36, 4524-4524.	1.6	36
160	Current Vaccination Strategies for Prostate Cancer. European Urology, 2012, 61, 290-306.	1.9	35
161	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. Current Drug Targets, 2012, 13, 1676-1686.	2.1	34
162	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 352-359.	1.9	34

#	Article	IF	CITATIONS
163	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer, 2018, 118, 1434-1441.	6.4	34
164	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. JAMA Oncology, 2017, 3, 68.	7.1	33
165	Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial Journal of Clinical Oncology, 2021, 39, 4532-4532.	1.6	32
166	PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210) Journal of Clinical Oncology, 2016, 34, 104-104.	1.6	32
167	FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression Journal of Clinical Oncology, 2020, 38, 489-489.	1.6	32
168	A nomogram including baseline prognostic factors to estimate the activity of secondâ€line therapy for advanced urothelial carcinoma. BJU International, 2014, 113, E137-43.	2.5	31
169	Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy. European Journal of Cancer, 2014, 50, 1321-1329.	2.8	31
170	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. International Journal of Oncology, 2014, 44, 5-16.	3.3	31
171	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2017, 198, 817-823.	0.4	31
172	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treatment Reviews, 2021, 97, 102187.	7.7	31
173	Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. European Urology Oncology, 2020, 3, 351-359.	5.4	31
174	Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. European Urology, 2013, 64, 994-1002.	1.9	30
175	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.4	30
176	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial Journal of Clinical Oncology, 2013, 31, LBA8-LBA8.	1.6	30
177	What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?. Cancer Treatment Reviews, 2013, 39, 366-374.	7.7	29
178	Loss of Sh3gl2/Endophilin A1 Is a Common Event in Urothelial Carcinoma that Promotes Malignant Behavior. Neoplasia, 2013, 15, 749-IN16.	5.3	28
179	Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. Journal of Urology, 2018, 199, 1149-1157.	0.4	28
180	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 2018, 119, 707-712.	6.4	28

#	Article	IF	CITATIONS
181	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	1.9	27
182	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Frontiers in Oncology, 2018, 8, 463.	2.8	27
183	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. International Journal of Clinical Oncology, 2020, 25, 165-174.	2.2	27
184	Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2013, 18, 558-567.	3.7	26
185	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	2.2	26
186	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. European Urology, 2018, 73, 800-806.	1.9	26
187	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. Journal of Urology, 2018, 200, 1207-1214.	0.4	26
188	Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2005, 23, 2521-2533.	1.6	25
189	Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU International, 2009, 104, 10-18.	2.5	25
190	Review: Castration-resistant prostate cancer: new science and therapeutic prospects. Therapeutic Advances in Medical Oncology, 2010, 2, 189-207.	3.2	25
191	Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. Journal of Translational Medicine, 2013, 11, 182.	4.4	25
192	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer, 2015, 15, 242.	2.6	25
193	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 624-633.	1.9	25
194	Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4. Biomedicines, 2018, 6, 85.	3.2	25
195	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research, 2018, 24, 4081-4088.	7.0	24
196	Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities. Nature Reviews Urology, 2019, 16, 433-445.	3.8	24
197	Chemotherapy for older patients with prostate cancer. BJU International, 2007, 99, 269-273.	2.5	23
198	Chemotherapy for Metastatic or Unresectable Bladder Cancer. Seminars in Oncology, 2007, 34, 135-144.	2.2	23

#	Article	IF	CITATIONS
199	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Molecular Cancer Research, 2019, 17, 1931-1944.	3.4	23
200	Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study Journal of Clinical Oncology, 2015, 33, 296-296.	1.6	23
201	Future Directions and Targeted Therapies in Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 361-376.	2.2	22
202	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European Urology, 2016, 69, 924-932.	1.9	22
203	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncológica, 2018, 57, 491-497.	1.8	22
204	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. Clinical Genitourinary Cancer, 2020, 18, e543-e556.	1.9	22
205	Management of Treatment-Related Toxicity with Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices. Hematology/Oncology Clinics of North America, 2011, 25, 893-915.	2.2	21
206	A new patientâ€focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU International, 2011, 107, 1190-1199.	2.5	21
207	Molecular targets on the horizon for kidney and urothelial cancer. Nature Reviews Clinical Oncology, 2013, 10, 557-570.	27.6	21
208	Combination Therapy in Metastatic Renal Cell Cancer. Seminars in Oncology, 2013, 40, 472-481.	2.2	21
209	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	1.6	21
210	The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. Cancer Treatment Reviews, 2017, 61, 82-93.	7.7	21
211	TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy Journal of Clinical Oncology, 2021, 39, TPS498-TPS498.	1.6	21
212	First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study Journal of Clinical Oncology, 2021, 39, 4508-4508.	1.6	21
213	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	7.0	21
214	Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors. Seminars in Oncology, 2008, 35, S34-S43.	2.2	20
215	Impact of Response to Prior Chemotherapy inÂPatients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications forÂTrial Design. Clinical Genitourinary Cancer, 2013, 11, 495-500.	1.9	20
216	Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents. Clinical Genitourinary Cancer, 2018, 16, e777-e784.	1.9	20

#	Article	IF	CITATIONS
217	FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols, 2020, 15, 2503-2518.	12.0	20
218	A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE) Journal of Clinical Oncology, 2021, 39, TPS504-TPS504.	1.6	20
219	Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Current Opinion in Urology, 2013, 23, 466-471.	1.8	19
220	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 120-126.	4.4	19
221	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) Journal of Clinical Oncology, 2018, 36, 410-410.	1.6	19
222	KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results Journal of Clinical Oncology, 2019, 37, 4546-4546.	1.6	19
223	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. European Urology, 2015, 67, 904-912.	1.9	18
224	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Review of Anticancer Therapy, 2010, 10, 825-835.	2.4	17
225	Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. European Journal of Cancer, 2012, 48, 1495-1502.	2.8	17
226	Diagnosis of Bladder Carcinoma. Surgical Pathology Clinics, 2015, 8, 677-685.	1.7	17
227	Angiogenesis as a therapeutic target in urothelial carcinoma. Nature Reviews Urology, 2016, 13, 306-307.	3.8	17
228	The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 755-760.	1.7	17
229	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	1.9	17
230	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. Journal of Clinical Investigation, 2021, 131, .	8.2	17
231	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial) Journal of Clinical Oncology, 2014, 32, 7-7.	1.6	17
232	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC) Journal of Clinical Oncology, 2017, 35, 4501-4501.	1.6	17
233	FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC) Journal of Clinical Oncology, 2018, 36, 4534-4534.	1.6	17
234	Defining "platinum-ineligible―patients with metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2022, 40, 4577-4577.	1.6	17

#	Article	IF	CITATIONS
235	Management of Castrate Resistant Prostate Cancer—Recent Advances and Optimal Sequence of Treatments. Current Urology Reports, 2013, 14, 174-183.	2.2	16
236	New Treatments for Bladder Cancer: When Will We Make Progress?. Current Treatment Options in Oncology, 2014, 15, 99-114.	3.0	16
237	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factorâ€targeted therapies. Cancer, 2016, 122, 2389-2398.	4.1	16
238	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU International, 2017, 119, 579-584.	2.5	16
239	The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treatment and Research, 2018, 175, 259-271.	0.5	16
240	Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis. Quality of Life Research, 2018, 27, 2759-2775.	3.1	16
241	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS ONE, 2015, 10, e0124711.	2.5	16
242	Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 272.e1-272.e9.	1.6	16
243	Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer, 1995, 75, 831-835.	4.1	15
244	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. Clinical Genitourinary Cancer, 2015, 13, 178-184.	1.9	15
245	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. European Urology, 2019, 76, 425-429.	1.9	15
246	Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?. European Urology Oncology, 2019, 2, 597-602.	5.4	15
247	Late recurrent metastasis in Wilms' tumour. Medical and Pediatric Oncology, 1994, 23, 158-161.	1.0	14
248	Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer and Metastasis Reviews, 2012, 31, 11-17.	5.9	14
249	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts. , 2016, 4, .		14
250	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, e961-e967.	1.9	14
251	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clinical Cancer Research, 2018, 24, 6115-6124.	7.0	14
252	Experience with sorafenib and the elderly patient. Medical Oncology, 2010, 27, 1359-1370.	2.5	13

#	Article	IF	CITATIONS
253	The effect of smoking on prostate cancer survival. European Journal of Cancer Prevention, 2015, 24, 335-339.	1.3	13
254	Enzalutamide in European and North American men participating in the AFFIRM trial. BJU International, 2015, 115, 41-49.	2.5	13
255	Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy Journal of Clinical Oncology, 2021, 39, 438-438.	1.6	13
256	Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis. British Journal of Cancer, 2022, 127, 313-320.	6.4	13
257	Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treatment Reviews, 2012, 38, 431-441.	7.7	12
258	Patient Eligibility and Trial Design for the Salvage Therapy ofÂAdvanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 395-398.	1.9	12
259	Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). , 2015, 3, .		12
260	Patterns of Bladder Preservation TherapyÂUtilization for Muscle-Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 405-413.	0.4	12
261	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Medicine, 2017, 6, 186-194.	2.8	12
262	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer, 2018, 16, e483-e490.	1.9	12
263	SPOPandFOXA1mutations are associated with PSA recurrence inERGwt tumors, andSPOPdownregulation withERGâ€rearranged prostate cancer. Prostate, 2019, 79, 1156-1165.	2.3	12
264	A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel Journal of Clinical Oncology, 2013, 31, 5013-5013.	1.6	12
265	A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE Journal of Clinical Oncology, 2016, 34, TPS4574-TPS4574.	1.6	12
266	Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. Critical Reviews in Oncology/Hematology, 2022, 174, 103683.	4.4	12
267	Cytologic Diagnosis in Bronchoalveolar Lavage Specimens. Chest, 1990, 98, 513-514.	0.8	11
268	Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC. European Urology Supplements, 2007, 6, 484-491.	0.1	11
269	Advances in the management of highâ€risk localised and metastatic prostate cancer. BJU International, 2012, 109, 8-13.	2.5	11
270	Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2015, 15, 151-156.	2.4	11

#	Article	IF	CITATIONS
271	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	1.9	11
272	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2–4NOMO Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. European Urology Oncology, 2019, 2, 248-256.	5.4	11
273	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European Urology Focus, 2019, 5, 242-249.	3.1	11
274	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. European Urology Oncology, 2020, 3, 671-679.	5.4	11
275	Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era. Minerva Urology and Nephrology, 2021, 73, 292-298.	2.5	11
276	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) Journal of Clinical Oncology, 2016, 34, TPS4576-TPS4576.	1.6	11
277	Overview of gemcitabine triplets in metastatic bladder cancer. Critical Reviews in Oncology/Hematology, 2003, 45, 191-197.	4.4	10
278	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 1-13.	2.3	10
279	Tackling the Bone with Alpha Emitters in Metastatic Castration-resistant Prostate Cancer Patients. European Urology, 2013, 63, 198-200.	1.9	10
280	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist, 2019, 24, 1348-1355.	3.7	10
281	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab Journal of Clinical Oncology, 2018, 36, 413-413.	1.6	10
282	Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology, 2022, 18, 2599-2614.	2.4	10
283	New chemotherapy combinations for advanced bladder cancer. Current Opinion in Urology, 2001, 11, 517-522.	1.8	9
284	INTERMITTENT CHEMOTHERAPY IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE CANCER. BJU International, 2007, 100, 490-492.	2.5	9
285	A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clinical and Translational Oncology, 2010, 12, 503-508.	2.4	9
286	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews, 2012, 38, 127-132.	7.7	9
287	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	2.5	9
288	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clinical Genitourinary Cancer, 2014, 12, 262-269.	1.9	9

#	Article	IF	CITATIONS
289	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. British Journal of Cancer, 2016, 115, 12-19.	6.4	9
290	Avelumab for the treatment of urothelial cancer. Expert Review of Anticancer Therapy, 2018, 18, 421-429.	2.4	9
291	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 7-14.e3.	1.9	9
292	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research, 2020, 26, 6122-6131.	7.0	9
293	KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy Journal of Clinical Oncology, 2015, 33, TPS4572-TPS4572.	1.6	9
294	Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study Journal of Clinical Oncology, 2015, 33, 297-297.	1.6	9
295	Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase la study Journal of Clinical Oncology, 2017, 35, 290-290.	1.6	9
296	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible <i>FGFR3</i> alterations Journal of Clinical Oncology, 2020, 38, TPS5095-TPS5095.	1.6	9
297	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. SSRN Electronic Journal, 0,	0.4	9
298	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 2022, 40, 1772-1782.	1.6	9
299	The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma. European Urology Supplements, 2008, 7, 55-62.	0.1	8
300	Reply to G. Sonpavde et al. Journal of Clinical Oncology, 2010, 28, e443-e444.	1.6	8
301	A new approach to second-line therapy for urothelial cancer?. Lancet Oncology, The, 2013, 14, 682-684.	10.7	8
302	Hyponatremia Associated with Worse Outcomes in Metastatic Renal Cell Cancer: A Potential Target for Intervention?. European Urology, 2014, 65, 731-732.	1.9	8
303	Incidental focal uptake in colorectal location on oncologic FDG PET and PET/CT studies: Histopathological findings and clinical significances. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 95-101.	0.0	8
304	Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, xiii-xiv.	2.2	8
305	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer, 2017, 3, 145-146.	0.4	8
306	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial Journal of Clinical Oncology, 2021, 39, 4520-4520.	1.6	8

#	Article	IF	CITATIONS
307	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist, 2021, 26, 1026-1034.	3.7	8
308	Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2017, 35, 4540-4540.	1.6	8
309	Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy. Clinical Genitourinary Cancer, 2022, 20, 132-138.	1.9	8
310	Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Medical Oncology, 2011, 28, 1379-1383.	2.5	7
311	Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncology, 2014, 10, 351-362.	2.4	7
312	The evolving role of enzalutamide on the treatment of prostate cancer. Future Oncology, 2016, 12, 607-616.	2.4	7
313	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European Urology Focus, 2018, 4, 937-945.	3.1	7
314	Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. , 2020, 8, e000419.		7
315	SPOP and <i>CHD1</i> alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. Prostate, 2021, 81, 1267-1277.	2.3	7
316	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer Journal of Clinical Oncology, 2015, 33, TPS4571-TPS4571.	1.6	7
317	FIDES-02, a phase lb/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations Journal of Clinical Oncology, 2020, 38, TPS590-TPS590.	1.6	7
318	Malignant Lymphoproliferative Diseases in HIV-Seropositive Patients: A study of 40 cases at a single institution in Spain. Acta Oncológica, 1995, 34, 75-82.	1.8	6
319	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB) Journal of Clinical Oncology, 2016, 34, 4524-4524.	1.6	6
320	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045 Journal of Clinical Oncology, 2017, 35, 4530-4530.	1.6	6
321	Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer Journal of Clinical Oncology, 2017, 35, 282-282.	1.6	6
322	Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial Journal of Clinical Oncology, 2018, 36, 4521-4521.	1.6	6
323	A phase ili, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC) Journal of Clinical Oncology, 2019, 37,	1.6	6
324	TPS409-TPS400. TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy Journal of Clinical Oncology, 2022, 40, TPS582-TPS582.	1.6	6

#	Article	IF	CITATIONS
325	Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. ClinicoEconomics and Outcomes Research, 2011, 3, 19.	1.9	5
326	Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemotherapy and Pharmacology, 2014, 73, 857-867.	2.3	5
327	Perioperative Therapy for Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 301-318.	2.2	5
328	Incomplete Cross-Resistance Between Taxanes forÂAdvanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clinical Genitourinary Cancer, 2015, 13, 250-256.	1.9	5
329	Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970–7. European Urology, 2016, 70, e71.	1.9	5
330	Cancer immunotherapy. Current Opinion in Urology, 2016, 26, 556-563.	1.8	5
331	Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 457-466.	2.8	5
332	Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, 344-352.	0.8	5
333	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in firstâ€line metastatic renal carcinoma (SUNRISES study). BJU International, 2020, 126, 559-567.	2.5	5
334	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. European Urology Oncology, 2021, 4, 502-505.	5.4	5
335	Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. Current Oncology Reports, 2021, 23, 24.	4.0	5
336	Metastatic urothelial carcinoma. Cancer Cell, 2021, 39, 583-585.	16.8	5
337	First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial Journal of Clinical Oncology, 2015, 33, 4503-4503.	1.6	5
338	Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials Journal of Clinical Oncology, 2016, 34, 73-73.	1.6	5
339	Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303 Journal of Clinical Oncology, 2018, 36, TPS4586-TPS4586.	1.6	5
340	Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100 Journal of Clinical Oncology, 2022, 40, 4560-4560.	1.6	5
341	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy Journal of Clinical Oncology, 2022, 40, 4559-4559.	1.6	5
342	The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival. European Urology, 2008, 54, 1192-1197.	1.9	4

#	Article	IF	CITATIONS
343	Predictive modelling in hormone-refractory prostate cancer (HRPC). Clinical and Translational Oncology, 2009, 11, 82-85.	2.4	4
344	Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncology, The, 2009, 10, 740.	10.7	4
345	Practical aspects of metastatic castrationâ€resistant prostate cancer management: patient case studies. BJU International, 2012, 109, 14-19.	2.5	4
346	False Positive 2-18Fluroro-deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients With Disseminated Seminoma and Post-Chemotherapy Residual Masses. Clinical Genitourinary Cancer, 2013, 11, 66-69.	1.9	4
347	Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. Critical Reviews in Oncology/Hematology, 2013, 88, 357-367.	4.4	4
348	Sunitinib malate in the treatment of urothelial cancer. Expert Opinion on Investigational Drugs, 2014, 23, 115-124.	4.1	4
349	Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma. Oncologist, 2014, 19, 917-918.	3.7	4
350	MP68-11 A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER. Journal of Urology, 2015, 193, .	0.4	4
351	Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?. Oncologist, 2015, 20, 461-463.	3.7	4
352	Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU International, 2015, 115, 854-855.	2.5	4
353	Antiangiogenesis to curb urothelial cancer. Lancet, The, 2017, 390, 2220-2221.	13.7	4
354	Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncology, 2017, 13, 2745-2758.	2.4	4
355	Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. Scientific Reports, 2020, 10, 20135.	3.3	4
356	Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 27-34.	1.6	4
357	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. Clinical Genitourinary Cancer, 2021, 19, 125-134.	1.9	4
358	Current Therapy for Metastatic Urothelial Carcinoma. Hematology/Oncology Clinics of North America, 2021, 35, 469-493.	2.2	4
359	Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer Journal of Clinical Oncology, 2014, 32, 3526-3526.	1.6	4
360	Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302 Journal of Clinical Oncology, 2014, 32, 14-14.	1.6	4

#	Article	IF	CITATIONS
361	A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes Journal of Clinical Oncology, 2015, 33, TPS4575-TPS4575.	1.6	4
362	Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas Journal of Clinical Oncology, 2017, 35, 4500-4500.	1.6	4
363	Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Future Oncology, 2022, 18, 2361-2371.	2.4	4
364	Early Results of the Value of p53 in Predicting Survival in a Homogeneous Cohort of Patients with Invasive Bladder Cancer Treated with a Neoadjuvant Carboplatin-Based Regimen (M-CAVI). Tumori, 1996, 82, 554-559.	1.1	3
365	Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence. European Urology Supplements, 2008, 7, 585-592.	0.1	3
366	Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer and Metastasis Reviews, 2010, 29, 1-10.	5.9	3
367	Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer and Metastasis Reviews, 2010, 29, 11-20.	5.9	3
368	Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opinion on Drug Safety, 2013, 12, 455-463.	2.4	3
369	Reply from Authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a Systematic Review and Meta-analysis of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol 2014;66:55–6. European Urology, 2014, 66, 57-58.	1.9	3
370	ls angiogenesis still an attractive target in metastatic castrationâ€resistant prostate cancer?. BJU International, 2015, 116, 500-501.	2.5	3
371	The "Artificial―Docetaxel Space: The Evolving Treatment Paradigm of Metastatic Castration-Resistant Prostate Cancer. European Urology, 2015, 67, 30-32.	1.9	3
372	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis. Clinical Genitourinary Cancer, 2017, 15, e1089-e1094.	1.9	3
373	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clinical Genitourinary Cancer, 2018, 16, e161-e167.	1.9	3
374	Immunotherapy in non-metastatic urothelial cancer: back to the â€~future'. Expert Opinion on Biological Therapy, 2019, 19, 685-695.	3.1	3
375	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. Journal of Urology, 2021, 205, 414-419.	0.4	3
376	Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100 Journal of Clinical Oncology, 2021, 39, 4525-4525.	1.6	3
377	Advances in the management of urothelial carcinoma: is immunotherapy the answer?. Expert Opinion on Pharmacotherapy, 2021, 22, 1743-1759.	1.8	3
378	Adjuvant immunotherapy in muscle-invasive urothelial carcinoma – Author's reply. Lancet Oncology, The, 2021, 22, e238.	10.7	3

#	Article	IF	CITATIONS
379	Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2014, 32, 4512-4512.	1.6	3
380	Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)—Interim analysis on safety Journal of Clinical Oncology, 2014, 32, 359-359.	1.6	3
381	Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA) Tj ETQq1 1 0.78431	41gBT/C)ve s lock 10 T
382	First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts) Journal of Clinical Oncology, 2018, 36, e16517-e16517.	1.6	3
383	Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma Journal of Clinical Oncology, 2018, 36, 426-426.	1.6	3
384	Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry Journal of Clinical Oncology, 2020, 38, 5026-5026.	1.6	3
385	266â€Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC). , 2020, , .		3
386	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial Journal of Clinical Oncology, 2022, 40, TPS588-TPS588.	1.6	3
387	Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?. Drugs and Aging, 2022, 39, 271-284.	2.7	3
388	Frequent Dose Delays and Growth Factor Requirements with the Sequential Doxorubicin-CMF Schedule. Acta OncolÃ ³ gica, 1997, 36, 701-704.	1.8	2
389	Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma. Cancer, 1998, 82, 878-885.	4.1	2
390	Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. European Journal of Cancer, 2009, 45, 2804-2809.	2.8	2
391	Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer. European Urology Supplements, 2009, 8, 448-452.	0.1	2
392	Stage II Disease, Elderly Patients, Secondary Neoplasms, and the MOSAIC Trial. Journal of Clinical Oncology, 2013, 31, 1609-1609.	1.6	2
393	MP61-09 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN AND ROBOT-ASSISTED RADICAL CYSTECTOMIES: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES. Journal of Urology, 2014, 191, .	0.4	2
394	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy forÂUrothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 185-192.	1.9	2
395	MP34-11 NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY. Journal of Urology, 2017, 197, .	0.4	2
396	Exploring Patterns of Mitomycin C Use in Community Practice Urology. Urology Practice, 2018, 5, 7-14.	0.5	2

#	Article	IF	CITATIONS
397	Changes in expectations for metastatic urothelial carcinoma. Nature Reviews Clinical Oncology, 2018, 15, 73-74.	27.6	2
398	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	3.0	2
399	Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncology, 2019, 5, 904.	7.1	2
400	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 934.e1-934.e9.	1.6	2
401	Endobronchial metastatic disease: Analysis of 32 cases. Journal of Surgical Oncology, 1996, 62, 249-252.	1.7	2
402	Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel Journal of Clinical Oncology, 2012, 30, 250-250.	1.6	2
403	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2013, 31, 301-301.	1.6	2
404	Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT) Journal of Clinical Oncology, 2014, 32, 4534-4534.	1.6	2
405	PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma Journal of Clinical Oncology, 2014, 32, 4552-4552.	1.6	2
406	Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel Journal of Clinical Oncology, 2014, 32, 5042-5042.	1.6	2
407	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy Journal of Clinical Oncology, 2014, 32, 353-353.	1.6	2
408	Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) Journal of Clinical Oncology, 2015, 33, 4524-4524.	1.6	2
409	Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma Journal of Clinical Oncology, 2015, 33, 4532-4532.	1.6	2
410	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies Journal of Clinical Oncology, 2015, 33, 4559-4559.	1.6	2
411	Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)—SOGUG 2011-02 Journal of Clinical Oncology, 2016, 34, 4529-4529.	1.6	2
412	Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study Journal of Clinical Oncology, 2017, 35, 5042-5042.	1.6	2
413	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival Journal of Clinical Oncology, 2017, 35, 346-346.	1.6	2
414	A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy Journal of Clinical Oncology, 2016, 34, 201-201.	1.6	2

#	Article	IF	CITATIONS
415	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC) Journal of Clinical Oncology, 2019, 37, 478-478.	1.6	2
416	Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052 Journal of Clinical Oncology, 2022, 40, 512-512.	1.6	2
417	Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2022, ,	1.6	2
418	Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma. Cancers, 2021, 13, 6235.	3.7	2
419	Chemotherapy in Metastatic Urothelial Cancer. American Journal of Cancer, 2002, 1, 23-31.	0.4	1
420	¹¹ Câ€METHIONINE POSITRONâ€EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PETâ€ EVALUATING METASTATIC TRANSITIONAL CELL CARCINOMA RESPONSE TO SUNITINIB THERAPY. BJU International, 2010, 106, 1249-1250.	CT) IN 2.5	1
421	Reply to G. Sonpavde et al. Journal of Clinical Oncology, 2010, 28, e208-e208.	1.6	1
422	Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU International, 2011, 107, 1-12.	2.5	1
423	Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2011;59:572–83. European Urology. 2011. 60. e39-e41.	1.9	1
424	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. Journal of Clinical Oncology, 2014, 32, 4171-4172.	1.6	1
425	Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer. BJU International, 2014, 114, 163-164.	2.5	1
426	MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÃVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302. Journal of Urology, 2014, 191, .	0.4	1
427	MP65-12 AN OPTIMIZED TREATMENT STRATEGY FOR HGT1 BLADDER CANCER BASED ON MICROSTAGING: RESULTS AT 5YEARS FOLLOW-UP IN 200 PATIENTS. Journal of Urology, 2014, 191, .	0.4	1
428	MP13-13 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN VS. MINIMALLY INVASIVE RADICAL NEPHROURETERECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES. Journal of Urology, 2014, 191, .	0.4	1
429	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clinical Genitourinary Cancer, 2017, 15, 509-512.e9.	1.9	1
430	A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma. Case Reports in Oncology, 2017, 10, 493-500.	0.7	1
431	Does it matter whether a T1 high-grade tumor is molecularly classified?. European Urology Oncology, 2019, 4, 837-842.	5.4	1
432	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5. European Urology, 2020, 77, 436-438.	1.9	1

#	Article	IF	CITATIONS
433	Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655–6. European Urology, 2021, 79, 657-658.	1.9	1
434	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy Journal of Clinical Oncology, 2014, 32, 336-336.	1.6	1
435	Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway and prognostic significance for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial cancer (UC) Journal of Clinical Oncology, 2014, 32, 358-358.	1.6	1
436	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort Journal of Clinical Oncology, 2015, 33, 4519-4519.	1.6	1
437	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma Journal of Clinical Oncology, 2015, 33, 311-311.	1.6	1
438	Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT) Journal of Clinical Oncology, 2015, 33, 318-318.	1.6	1
439	miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel Journal of Clinical Oncology, 2015, 33, 364-364.	1.6	1
440	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2015, 33, 422-422.	1.6	1
441	Genomic evolution in muscle-invasive bladder cancer resistant to neoadjuvant chemotherapy Journal of Clinical Oncology, 2016, 34, 4518-4518.	1.6	1
442	An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel Journal of Clinical Oncology, 2016, 34, e16509-e16509.	1.6	1
443	Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors Journal of Clinical Oncology, 2016, 34, 385-385.	1.6	1
444	Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project Journal of Clinical Oncology, 2016, 34, 405-405.	1.6	1
445	Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT) Journal of Clinical Oncology, 2016, 34, 422-422.	1.6	1
446	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis Journal of Clinical Oncology, 2017, 35, 332-332.	1.6	1
447	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma Journal of Clinical Oncology, 2018, 36, 451-451.	1.6	1
448	Genomic characterization of metastatic urothelial carcinoma Journal of Clinical Oncology, 2013, 31, 247-247.	1.6	1
449	A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity Journal of Clinical Oncology, 2015, 33, 15-15.	1.6	1
450	Genomic predictors of recurrence (R) or progression (P) in high grade T1 (HGT1) non-muscle invasive (NMI) bladder cancer Journal of Clinical Oncology, 2016, 34, 4539-4539.	1.6	1

#	Article	IF	CITATIONS
451	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors Journal of Clinical Oncology, 2018, 36, 3036-3036.	1.6	1
452	Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma. Cancer Research, 2019, 79, CT177-CT177.	0.9	1
453	Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder. Expert Review of Anticancer Therapy, 2022, 22, 259-267.	2.4	1
454	Health-related quality of life (HRQoL) for patients with advanced/metastatic urothelial carcinoma (UC) enrolled in KEYNOTE-052 who are potentially platinum ineligible Journal of Clinical Oncology, 2022, 40, 4561-4561.	1.6	1
455	Advances in the Management of Metastatic Renal Cell Cancer. European Urology Supplements, 2009, 8, 758-761.	0.1	0
456	What are the expected developments in the medical treatment of bladder cancer. European Journal of Cancer, 2011, 47, S294-S297.	2.8	0
457	The optimize project: beyond first-line therapy in metastatic renal cell carcinoma. Cancer and Metastasis Reviews, 2012, 31, 1-2.	5.9	0
458	Perspectives on Treatment of Metastatic Castrationâ€Resistant Prostate Cancer. Oncologist, 2013, 18, 775-775.	3.7	0
459	Perspectives on Treatment of Metastatic Castrationâ€Resistant Prostate Cancer. Oncologist, 2013, 18, 971-971.	3.7	0
460	In Reply. Oncologist, 2014, 19, 305-305.	3.7	0
461	MP13-14 THE IMPACT OF SURGEON VOLUME ON THE MORBIDITY AND COSTS OF NEPHROURETERECTOMY IN THE UNITED STATES: AÂCONTEMPORARY POPULATION-BASED ANALYSIS. Journal of Urology, 2014, 191, .	0.4	0
462	MP65-14 PROPOSAL FOR INCLUDING SUBSTAGING OF HGT1 BLADDER CANCER IN THE TNM CLASSIFICATION: A SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON 2678 PATIENTS. Journal of Urology, 2014, 191, .	0.4	0
463	MP56-02 PROGNOSTIC FACTORS FOR HIGH-GRADE T1 BLADDER CANCER: A META-ANALYSIS BASED ON 7,486 PATIENTS. Journal of Urology, 2014, 191, .	0.4	0
464	MP60-14 TRENDS IN URINARY DIVERSION AMONG PATIENTS UNDERGOING RADICAL CYSTECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS. Journal of Urology, 2014, 191, .	0.4	0
465	Reply to K. Lu. Journal of Clinical Oncology, 2015, 33, 2716-2717.	1.6	0
466	Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127–136. European Journal of Cancer, 2016, 68, 196-197.	2.8	0
467	PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA. Journal of Urology, 2016, 195, .	0.4	0
468	MP63-06 RACIAL DISPARITIES IN QUALITY METRICS OF MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2016, 195, .	0.4	0

#	Article	IF	CITATIONS
469	Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?. European Urology, 2016, 69, 574-575.	1.9	Ο
470	Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer — At What Cost? Eur Urol 2016;69:642–44. European Urology, 2016, 69, 644-645.	1.9	0
471	PD62-12 COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR LOCALIZED MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. Journal of Urology, 2017, 197, .	0.4	0
472	â€~Working toward understanding oligo and polymetastatic prostate cancer'. Current Opinion in Urology, 2017, 27, 532.	1.8	0
473	PD57-03 ASSESSMENT OF THE ECOLOGICAL ASSOCIATION BETWEEN TOBACCO SMOKING EXPOSURE AND BLADDER CANCER INCIDENCE OVER THE PAST HALF-CENTURY IN THE UNITED STATES. Journal of Urology, 2017, 197, .	0.4	0
474	MP34-19 EFFECT OF HISTOLOGICAL VARIANTS ON THE OUTCOMES OF RADICAL CYSTECTOMY FOR NON-METASTATIC MUSCLE-INVASIVE URINARY BLADDER CANCER. Journal of Urology, 2017, 197, .	0.4	0
475	PD67-09 COMPARATIVE EFFECTIVNESS OF ROBOT-ASSISTED VS. OPEN RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.4	Ο
476	Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion–Positive Metastatic Urothelial Carcinoma. JCO Precision Oncology, 2018, 2, 1-6.	3.0	0
477	Cytotoxic Chemotherapy for Advanced Bladder and Upper Tract Cancer. , 2021, , 289-304.		0
478	Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens Journal of Clinical Oncology, 2021, 39, 459-459.	1.6	0
479	Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol 2021;79:428–9. European Urology, 2021, 79, e119-e120.	1.9	0
480	Treatment of metastatic cancer. , 2008, , 225-234.		0
481	Abstract 1168: Urothelial cell carcinomas harbor very frequent mutations in FGFR3-PI3K-AKT pathway and highest prevalence of mutations is related to low-grade tumors. , 2010, , .		0
482	Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy Journal of Clinical Oncology, 2012, 30, 291-291.	1.6	0
483	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2013, 31, 260-260.	1.6	0
484	Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC) Journal of Clinical Oncology, 2013, 31, 279-279.	1.6	0
485	Abstract 4066: Loss of Sh3gl2/endophilin A1 is an early event in urothelial carcinoma that regulates malignant behavior , 2013, , .		0
486	Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib Journal of Clinical Oncology, 2014, 32, 537-537.	1.6	0

#	Article	IF	CITATIONS
487	Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies Journal of Clinical Oncology, 2014, 32, 330-330.	1.6	Ο
488	Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience Journal of Clinical Oncology, 2014, 32, 235-235.	1.6	0
489	External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2014, 32, 4542-4542.	1.6	0
490	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors Journal of Clinical Oncology, 2014, 32, 4514-4514.	1.6	0
491	Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials Journal of Clinical Oncology, 2014, 32, e15558-e15558.	1.6	0
492	Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors Journal of Clinical Oncology, 2014, 32, 4511-4511.	1.6	0
493	Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results Journal of Clinical Oncology, 2014, 32, e16088-e16088.	1.6	0
494	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC) Journal of Clinical Oncology, 2015, 33, 365-365.	1.6	0
495	Genomic landscape of high-grade T1 micropapillary bladder tumors Journal of Clinical Oncology, 2015, 33, 299-299.	1.6	Ο
496	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis Journal of Clinical Oncology, 2015, 33, 351-351.	1.6	0
497	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials Journal of Clinical Oncology, 2015, 33, 369-369.	1.6	0
498	Role of <i>miR-21</i> , <i>miR372</i> , and <i> E2F1</i> as biomarkers predicting outcome in cisplatin-treated bladder cancer patients Journal of Clinical Oncology, 2015, 33, 4530-4530.	1.6	0
499	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2015, 33, 4527-4527.	1.6	Ο
500	Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy Journal of Clinical Oncology, 2015, 33, e15518-e15518.	1.6	0
501	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials Journal of Clinical Oncology, 2015, 33, e15520-e15520.	1.6	0
502	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data Journal of Clinical Oncology, 2015, 33, 4560-4560.	1.6	0
503	Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC) Journal of Clinical Oncology, 2015, 33, e15519-e15519.	1.6	0
504	Contemporary use of lymph node dissection at nephroureterectomy in treating upper tract urothelial carcinoma: A US population-based analysis Journal of Clinical Oncology, 2015, 33, e15634-e15634.	1.6	0

#	Article	IF	CITATIONS
505	Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. , 2015, , .		0
506	Chemotherapy treatment patterns and survival outcomes in patients with visceral metastatic upper tract urothelial cell carcinoma Journal of Clinical Oncology, 2016, 34, 415-415.	1.6	0
507	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report Journal of Clinical Oncology, 2016, 34, 450-450.	1.6	Ο
508	Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC) Journal of Clinical Oncology, 2016, 34, 431-431.	1.6	0
509	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2016, 34, 386-386.	1.6	Ο
510	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center Journal of Clinical Oncology, 2016, 34, 33-33.	1.6	0
511	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2016, 34, 442-442.	1.6	0
512	The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT) Journal of Clinical Oncology, 2016, 34, e16026-e16026.	1.6	0
513	Genomic landscape of micropapillary nonmuscle-invasive bladder cancer Journal of Clinical Oncology, 2016, 34, e16028-e16028.	1.6	0
514	Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI) Journal of Clinical Oncology, 2016, 34, e16129-e16129.	1.6	0
515	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications Journal of Clinical Oncology, 2016, 34, 4535-4535.	1.6	Ο
516	Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2016, 34, 4536-4536.	1.6	0
517	Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients Journal of Clinical Oncology, 2016, 34, 3068-3068.	1.6	0
518	Fixed tissue ChIP-seq (FiT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles Journal of Clinical Oncology, 2016, 34, 4541-4541.	1.6	0
519	Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project. , 2016, , .		0
520	A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN) Journal of Clinical Oncology, 2017, 35, 285-285.	1.6	0
521	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study Journal of Clinical Oncology, 2017, 35, 4532-4532.	1.6	0
522	Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer Journal of Clinical Oncology, 2017, 35, 4512-4512.	1.6	0

#	Article	IF	CITATIONS
523	Prognostic impact of primary tumor location in advanced urothelial carcinoma: The EORTC series Journal of Clinical Oncology, 2017, 35, e16034-e16034.	1.6	Ο
524	Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials Journal of Clinical Oncology, 2017, 35, e16012-e16012.	1.6	0
525	Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis Journal of Clinical Oncology, 2017, 35, e16001-e16001.	1.6	ο
526	Abstract 2918: Analysis of matched pre and post cisplatin-treated muscle-invasive bladder cancer reveals a candidate cisplatin mutational signature. , 2017, , .		0
527	Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study Journal of Clinical Oncology, 2018, 36, 448-448.	1.6	Ο
528	FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians Journal of Clinical Oncology, 2018, 36, 465-465.	1.6	0
529	Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC Journal of Clinical Oncology, 2018, 36, 4539-4539.	1.6	ο
530	Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design Journal of Clinical Oncology, 2018, 36, 4535-4535.	1.6	0
531	Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2018, 36, 4529-4529.	1.6	ο
532	Comprehensive genomic characterization of urothelial carcinomas Journal of Clinical Oncology, 2018, 36, 4527-4527.	1.6	0
533	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets Journal of Clinical Oncology, 2019, 37, 4535-4535.	1.6	0
534	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival Journal of Clinical Oncology, 2019, 37, e16017-e16017.	1.6	0
535	A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC) Journal of Clinical Oncology, 2019, 37,	1.6	0
536	Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2020, 38, 467-467.	1.6	0
537	Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens Journal of Clinical Oncology, 2020, 38, e17005-e17005.	1.6	ο
538	Editorial Comment. Journal of Urology, 2020, 204, 69-70.	0.4	0
539	Abstract 3662: FiTAc-seq: Fixed-Tissue ChIP-seq for H3K27Ac profiling and super-enhancer analysis on FFPE tissues. , 2020, , .		0
540	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation Journal of Clinical Oncology, 2022, 40, 569-569.	1.6	0

#	Article	IF	CITATIONS
541	Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361 Journal of Clinical Oncology, 2022, 40, 519-519.	1.6	0
542	Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials Journal of Clinical Oncology, 2022, 40, 516-516.	1.6	0
543	Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology. , 2019, , .		Ο